These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 10687144)
21. Radiotherapy combined with intratumoral dendritic cell vaccination enhances the therapeutic efficacy of adoptive T-cell transfer. Teitz-Tennenbaum S; Li Q; Davis MA; Wilder-Romans K; Hoff J; Li M; Chang AE J Immunother; 2009; 32(6):602-12. PubMed ID: 19483649 [TBL] [Abstract][Full Text] [Related]
22. Recruitment of host CD8+ T cells by tumor-infiltrating lymphocytes and recombinant interleukin-2 during adoptive immunotherapy of cancer. Burger UL; Chang MP; Goedegebuure PS; Eberlein TJ; Adams-Hodgins S Surgery; 1995 Mar; 117(3):325-33. PubMed ID: 7878540 [TBL] [Abstract][Full Text] [Related]
23. In vivo photolabeling of tumor-infiltrating cells reveals highly regulated egress of T-cell subsets from tumors. Torcellan T; Hampton HR; Bailey J; Tomura M; Brink R; Chtanova T Proc Natl Acad Sci U S A; 2017 May; 114(22):5677-5682. PubMed ID: 28507145 [TBL] [Abstract][Full Text] [Related]
24. Myeloid differentiation treatment to diminish the presence of immune-suppressive CD34+ cells within human head and neck squamous cell carcinomas. Young MR; Wright MA; Pandit R J Immunol; 1997 Jul; 159(2):990-6. PubMed ID: 9218621 [TBL] [Abstract][Full Text] [Related]
25. Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. Sharma S; Stolina M; Luo J; Strieter RM; Burdick M; Zhu LX; Batra RK; Dubinett SM J Immunol; 2000 May; 164(9):4558-63. PubMed ID: 10779757 [TBL] [Abstract][Full Text] [Related]
26. Helper-independent, L-selectinlow CD8+ T cells with broad anti-tumor efficacy are naturally sensitized during tumor progression. Peng L; Kjaergaard J; Plautz GE; Weng DE; Shu S; Cohen PA J Immunol; 2000 Nov; 165(10):5738-49. PubMed ID: 11067932 [TBL] [Abstract][Full Text] [Related]
27. Suppression of T cell proliferation by tumor-induced granulocyte-macrophage progenitor cells producing transforming growth factor-beta and nitric oxide. Young MR; Wright MA; Matthews JP; Malik I; Prechel M J Immunol; 1996 Mar; 156(5):1916-22. PubMed ID: 8596044 [TBL] [Abstract][Full Text] [Related]
28. Adoptive immunotherapy of advanced tumors with CD62 L-selectin(low) tumor-sensitized T lymphocytes following ex vivo hyperexpansion. Wang LX; Chen BG; Plautz GE J Immunol; 2002 Sep; 169(6):3314-20. PubMed ID: 12218152 [TBL] [Abstract][Full Text] [Related]
29. Antitumor mechanism of recombinant murine interleukin-12 vaccine. Yin X; Yan X; Yang Q; Cao H; Liang H Cancer Biother Radiopharm; 2010 Jun; 25(3):263-8. PubMed ID: 20578831 [TBL] [Abstract][Full Text] [Related]
31. Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy. Winter H; Hu HM; McClain K; Urba WJ; Fox BA J Immunol; 2001 Jun; 166(12):7370-80. PubMed ID: 11390488 [TBL] [Abstract][Full Text] [Related]
32. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression. Huang H; Li F; Gordon JR; Xiang J Cancer Res; 2002 Apr; 62(7):2043-51. PubMed ID: 11929823 [TBL] [Abstract][Full Text] [Related]
33. Cytokine-containing gelfoam implants at a postsurgical tumor excision site to stimulate local immune reactivity. Young MR Int J Cancer; 2006 Jul; 119(1):133-8. PubMed ID: 16450395 [TBL] [Abstract][Full Text] [Related]
34. Effect of interleukin-1 alpha on the in vitro activation of tumor-draining lymph node cells for adoptive immunotherapy. Hammel JM; Tuck MK; Hain JM; Chang AE; Sondak VK J Immunother Emphasis Tumor Immunol; 1994 Jul; 16(1):1-12. PubMed ID: 8081555 [TBL] [Abstract][Full Text] [Related]
35. Antibodies to colony-stimulating factors block Lewis lung carcinoma cell stimulation of immune-suppressive bone marrow cells. Young MR; Wright MA; Young ME Cancer Immunol Immunother; 1991; 33(3):146-52. PubMed ID: 1675153 [TBL] [Abstract][Full Text] [Related]
36. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma. Jassar AS; Suzuki E; Kapoor V; Sun J; Silverberg MB; Cheung L; Burdick MD; Strieter RM; Ching LM; Kaiser LR; Albelda SM Cancer Res; 2005 Dec; 65(24):11752-61. PubMed ID: 16357188 [TBL] [Abstract][Full Text] [Related]
37. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection. Dobrzanski MJ; Reome JB; Dutton RW J Immunol; 2001 Jul; 167(1):424-34. PubMed ID: 11418679 [TBL] [Abstract][Full Text] [Related]
38. Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin-12, or GM-CSF. Aruga E; Aruga A; Arca MJ; Lee WM; Yang NS; Smith JW; Chang AE Cancer Gene Ther; 1997; 4(3):157-66. PubMed ID: 9171934 [TBL] [Abstract][Full Text] [Related]
39. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents. Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033 [TBL] [Abstract][Full Text] [Related]
40. TLR7 ligand augments GM-CSF-initiated antitumor immunity through activation of plasmacytoid dendritic cells. Narusawa M; Inoue H; Sakamoto C; Matsumura Y; Takahashi A; Inoue T; Watanabe A; Miyamoto S; Miura Y; Hijikata Y; Tanaka Y; Inoue M; Takayama K; Okazaki T; Hasegawa M; Nakanishi Y; Tani K Cancer Immunol Res; 2014 Jun; 2(6):568-80. PubMed ID: 24830413 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]